Acromesomelic dysplasia, Grebe type

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:2098OMIM:200700Q78.8
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Acromesomelic dysplasia, Grebe type (also known as Grebe chondrodysplasia or Brazilian achondrodysplasia) is a rare, severe skeletal disorder characterized by marked shortening and malformation of the limbs, particularly affecting the middle (mesomelic) and distal (acromelic) segments. The condition follows a characteristic proximal-to-distal gradient of severity, meaning the hands and feet are more severely affected than the forearms and lower legs, which in turn are more affected than the upper arms and thighs. The hands and feet may show extremely short, malformed digits (brachydactyly) or even rudimentary, ball-shaped digits with fusion of finger and toe bones (synostosis). The long bones of the limbs are shortened and often bowed, while the axial skeleton (spine and trunk) is relatively spared, resulting in a disproportionately short-limbed stature. This condition is caused by homozygous or compound heterozygous mutations in the GDF5 gene (also known as CDMP1), which encodes growth/differentiation factor 5, a member of the bone morphogenetic protein family critical for cartilage and bone development. The GDF5 protein plays an essential role in limb morphogenesis and joint formation. Loss-of-function mutations in this gene disrupt normal skeletal patterning, particularly in the appendicular skeleton. The condition was first described in a large consanguineous family in Brazil by Grebe in 1952. There is currently no cure or disease-specific treatment for Grebe type acromesomelic dysplasia. Management is supportive and symptomatic, focusing on orthopedic interventions to address limb deformities and improve mobility, physical therapy, and adaptive devices to assist with daily activities. Genetic counseling is recommended for affected families. Intelligence and life expectancy are typically normal. Early diagnosis can be made prenatally or at birth based on clinical and radiographic findings, and molecular genetic testing of the GDF5 gene can confirm the diagnosis.

Also known as:

Clinical phenotype terms— hover any for plain English:

Fibular hypoplasiaHP:0003038Short tibiaHP:0005736Aplasia/Hypoplasia involving the metacarpal bonesHP:0005914Disproportionate short-limb short statureHP:0008873SarcomaHP:0100242Aplasia of the middle phalanges of the toesHP:0100387
Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Acromesomelic dysplasia, Grebe type.

View clinical trials →

No actively recruiting trials found for Acromesomelic dysplasia, Grebe type at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Acromesomelic dysplasia, Grebe type community →

No specialists are currently listed for Acromesomelic dysplasia, Grebe type.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Acromesomelic dysplasia, Grebe type.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Acromesomelic dysplasia, Grebe typeForum →

No community posts yet. Be the first to share your experience with Acromesomelic dysplasia, Grebe type.

Start the conversation →

Latest news about Acromesomelic dysplasia, Grebe type

No recent news articles for Acromesomelic dysplasia, Grebe type.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Acromesomelic dysplasia, Grebe type

What is Acromesomelic dysplasia, Grebe type?

Acromesomelic dysplasia, Grebe type (also known as Grebe chondrodysplasia or Brazilian achondrodysplasia) is a rare, severe skeletal disorder characterized by marked shortening and malformation of the limbs, particularly affecting the middle (mesomelic) and distal (acromelic) segments. The condition follows a characteristic proximal-to-distal gradient of severity, meaning the hands and feet are more severely affected than the forearms and lower legs, which in turn are more affected than the upper arms and thighs. The hands and feet may show extremely short, malformed digits (brachydactyly) or

How is Acromesomelic dysplasia, Grebe type inherited?

Acromesomelic dysplasia, Grebe type follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Acromesomelic dysplasia, Grebe type typically begin?

Typical onset of Acromesomelic dysplasia, Grebe type is neonatal. Age of onset can vary across affected individuals.